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Abstract 
Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), 
which has been rarely associated with aseptic meningitis. We report a case of aseptic 
meningitis with first symptoms about 9 hours after the first administration of cetuximab in a 
67-year-old male with recurrent advanced oropharyngeal squamous cell carcinoma and 
review the literature to identify key signs and symptoms of this condition. Besides the case 
description a MEDLINE search was performed. In five patients identified in the literature and 
the patient presented here the leading signs and symptoms included headache, neck stiffness 
and high fever developing within few hours after first cetuximab administration. 
Cerebrospinal fluid (CSF) analysis revealed severe pleocytosis (range = 528-2300/µl) with 
dominance of neutrophils (≥87%). Clinical recovery within 1-2 weeks was accompanied by 
normalization of CSF cell count within 4 to 7 days. Re-challenge with cetuximab at a reduced 
dose caused recurrent aseptic meningitis in one of three patients. In summary, aseptic 
meningitis is a rare complication after first cetuximab exposure the clinician should be aware 
of. CSF analysis is the key and usually recovery is complete within days to weeks after 
withdrawal of the drug. Re-challenge may be considered but bears the risk of recurrence. 
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Cetuximab, a chimeric monoclonal antibody against the epidermal growth factor receptor 
(EGFR) has demonstrated activity as a single agent and in combination with chemotherapy or 
radiation in the treatment of metastatic or recurrent squamous cell cancer of head and neck, 
and in colorectal adenocarcinoma [1, 2]. Aseptic meningitis has been observed as a rare 
complication of cetuximab administration. 
Here we report aseptic meningitis after the first cetuximab administration (400mg/m2) in a 67-
year-old male treated for advanced oropharyngeal squamous cell carcinoma progressing on 
prior platinum-based treatment. Approximately nine hours after cetuximab infusion the 
patient complained of headache, showing neck stiffness, fever (39.2°C) and psychomotor 
slowing. Cranial computed tomography revealed leucencephalopathy, but no other 
abnormalities. Cerebrospinal fluid (CSF) analysis (see Table 1) demonstrated an elevated cell 
count (1413/µl; normal range: 0-4/µl) with 92% neutrophil granulocytes, 8% macrophages 
and no cancer cells. Gram staining was negative. CSF protein was elevated (1.786 g/l; normal 
range 0.2-0.4g/l), while glucose was normal (3.5 mmol/l, normal range 2.7 to 4.2 mmol/l) and 
lactate was only slightly elevated (3.0 mmol/l, normal range 1.7 to 2.6 mmol/l). Antibiotic and 
antiviral treatment was initiated with ceftazidim, vancomycin, amoxicillin and aciclovir plus 
dexamethasone. Treatment was stopped a few days later when PCR of neurotropic viruses 
(herpes simplex virus 1&2, varicella-zoster virus, cytomegalovirus, Epstein-Barr virus), 
bacterial cultures/staining and fungal staining returned negative. We therefore interpreted the 
patient’s condition as aseptic meningitis related to cetuximab. The patient gradually improved 
over the following days. Repeat CSF analysis eight days after admission (see Table 1) showed 
normalization of cell count (1/µl); while CSF protein was still elevated (0.682 g/l). CSF 
glucose (4.0 mmol/l) and lactate (1.5 mmol/l) levels were normal and oligoclonal bands were 
negative. Another seven days later, CSF protein level had normalized, too (0.359 g/l). The 
patient was discharged for rehabilitation four weeks after cetuximab treatment. Re-challenge 
with rituximab was not considered because of the reduced general condition due to tumor 
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progression and comorbidities (end stage renal failure). The patient died six weeks later 
probably related to cardiac arrhythmias. 
 
A MEDLINE-search (‘cetuximab AND aseptic meningitis’) identified three publications 
reporting on five patients (Table 2) [3-5]. Dose (400mg/m2) and application (rate=2h; first 
administration) of cetuximab were identical and symptom-onset was delayed by a few hours. 
Clinical presentation was similar with severe headaches, high fever and neck stiffness. CSF 
analysis revealed pleocytosis (range=528-2300/µl) with a dominance of neutrophil 
granulocytes (≥87%). All patients recovered, usually within one week, as also reflected by 
normalization of CSF cell count. While re-challenge with cetuximab (with dose reduced to 
250mg/m2) was feasible in two cases [5], recurrent aseptic meningitis was reported in another 
case [4]. 
A search in the WHO Global Database of Individual Case Safety Reports (ICSR) (‘cetuximab 
AND aseptic meningitis’) identified 21 cases (2005-2014) from a total of 15.456 ICSRs 
involving cetuximab, but no further information about clinical presentation, recovery or CSF 
results was available. 
 
Aseptic meningitis must be recognized as a rare and self-limiting adverse event that usually 
occurs within few hours after the first cetuximab administration. The combination of sudden 
headache, neck stiffness and high fever should prompt immediate CSF analysis including a 
broad search for bacterial, fungal or viral infections. Whereas the initial CSF inflammatory 
response is severe, a remarkably fast normalization of the CSF cell count accompanied by a 
rapid reduction of CSF protein is characteristic. Based on five published cases and 21 cases in 
the ICSR database, aseptic meningitis might be a very rare event after cetuximab treatment. 
The crossing of IgG over the blood-brain barrier might play a role in its pathogenesis [4]. 
Drug-induced meningitis as a diagnosis of exclusion was reported with other therapeutic 
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antibodies too, most frequently with the application of intravenous immunoglobulins (IVIGs) 
[6, 7]. Slowing the infusion rate, reducing the dose and premedication with steroids was 
proposed [5] in analogy to recommendations for the application of IVIGs [6, 7]. This 
approach was associated with lack of recurrence only in two of three cases.  
In summary, because of its characteristic clinical presentation, tight temporal association to 
the first cetuximab application and negative CSF cultures/serologies, the clinician can identify 
this rare and self-limiting adverse event reliably. While antibiotic and virostatic treatment is 
initially advised, symptomatic treatment is sufficient as soon as CSF cultures/serologies return 
negative. Prognosis is usually good with complete recovery within 1-2 weeks. The decision 
for re-challenge with cetuximab must be made on an individual basis, but bears the risk of 
recurrence.  
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Tables 
Table 1: CSF– evolvement over time after application of cetuximab (=day 1) 
parameter day 1 day 8 day 15 
cell count  
(normal range: 0-4/µl) 
1413 1 1 
neutrophils (%) 92% NA NA 
CSF protein  
(normal range: 0.2-0.4g/l) 
1.786 0.682 0.359 
glucose  
(normal range 2.7 to 4.2 mmol/l) 
3.5 4.0 2.8 
lactate  
(normal range 1.7 to 2.6 mmol/l) 
3.0 1.5 1.7 
PCR  
(cytomegalovirus, Epstein-Barr 
virus, herpes simplex virus 1&2, 
varicella-zoster virus) 
negative NA NA 
microbiology  
(Cytosin- and periodic-acid-
Schiff-staining) 
negative NA NA 
oligoclonal bands NA negative NA 
cancer cells negative NA NA 
 
Abbreviations: CSF=cerebrospinal fluid; NA=not available; PCR=polymerase chain reaction 
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Table 2: characteristics of the five reported cases in the literature * and comparison with the presented case 
study case #, 
age, 
gender 
type of cancer 
/ indication 
for cetuximab 
cetuximab dose, 
premedication 
symptoms and signs 
(onset), imaging 
initial CSF analysis 
(cell count, protein 
level) 
follow-up CSF 
analysis 
treatment, recovery re-challenge 
Emani & 
Zaiden 
2012 [4] 
1,  
54y, f 
squamous 
maxillary 
cancer (stage 
IVb) 
400mg/m2  (first 
application), yes 
(diphenhydramine 
50mg i.v.) 
frontal headache, 
neck discomfort, 
39.9°C fever (few 
hours after 
infusion), brain CT 
(normal) 
1025/µl with 92% 
neutrophils, protein 
1.65g/l, normal 
glucose level, neg. 
bacterial culture, 
PCRs (HSV) neg. 
NA empirical antibiotic 
tx. Resolution of sx, 
no complications. 
positive re-challenge after 4 
weeks (250mg/m2), recurrent 
CSF pleocytosis (715/µl, 93% 
neurophils), protein 1.22g/l, 
premedication: 
diphenhydramine, no steroids † 
Feinstein 
et al. 
2009 [5] 
2, 
45y, m 
recurrent 
laryngeal 
squamous cell 
carcinoma  
400mg/m2  (first 
application, 
duration 2h), yes 
(diphenhydramine 
50mg i.v.) 
frontal headache, 
38.9°C fever (few 
hours after 
infusion), brain 
imaging NR 
2300/µl with 98% 
neutrophils, protein 
1.04g/l, normal 
glucose level, neg. 
cultures 
“resolution of 
neutrophilic 
pleocytosis”, 
normal protein 
levels (day 4) 
empirical antibiotic 
tx, aciclovir. No 
information about 
recovery 
negative re-challenge after 1 
week (250mg/m2, 
premedication: dexamethasone, 
diphenhydramine) without 
adverse events 
 3, 
42y, m 
locally 
advanced 
squamous cell 
carcinoma of 
right tonsil 
400mg/m2  (first 
application, 
duration 2h), yes 
(diphenhydramine 
50mg i.v.) 
severe frontal 
headache, 39.4°C 
fever, neck 
stiffness, 
photophobia (≈8h 
after infusion), brain 
imaging NR 
2267/µl with 90% 
neutrophils, protein 
1.46g/l, normal 
glucose level, neg. 
cultures 
“no white blood 
cells”, elevated 
but improved 
protein 
(69mg/dl) 
empirical antibiotic 
tx, acyclovir, 
dexamethasone. 
Recovery from 
meningeal sx after 
12 days 
negative re-challenge after 2 
weeks (250mg/m2, 
premedication: dexamethasone, 
diphenhydramine, famotidine) 
without adverse events 
Nagovski
y et al. 
2010 [3] 
4, 
78y, f 
NSCLC (stage 
IIIA) 
400mg/m2  (first 
application, 
duration NR), NR 
severe headache, 
nausea, vomiting, 
neck stiffness (few 
hours after 
infusion), brain CT 
(normal) 
528/µl with 87% 
neutrophils ‡, 
“modestly elevated 
protein”, normal 
glucose levels 
NA empirical antibiotic 
tx (stopped after 
infection was ruled 
out). Recovery w/o 
neurological 
sequelae. 
NR 
 5, 
59y, m 
metastatic 
NSCLC 
400mg/m2  (first 
application, 
duration NR), NR 
acute 
encephalopathy 
(few hours after 
infusion), brain CT 
and MRI (normal) 
cell count and 
fraction of 
neutrophils NA §, 
protein 1.16g/l, 
glucose 2.8mmol/l, 
neg. cultures 
NA empirical antibiotic 
tx (stopped after 
infection was ruled 
out). Recovery 
“within several 
days” 
NR 
Present 
case 
6, 
67y, m 
recurrent 
advanced 
oropharyngeal 
squamous cell 
carcinoma 
400mg/m2  (first 
application, 
duration 2h), yes 
(clemastine 2mg 
p.o.) 
headache, mutism, 
hypertension, neck 
stiffness, 39.2°C 
fever (≈9h after 
infusion), brain CT 
and MRI (non-
diagnostic) 
1413/µl (normal 
range 0-4/µl) with 
92% neutrophils, 
protein 1.79g/l 
(normal range 
<0.4), normal 
glucose level 
(3.5mmol/l), neg. 
cultures / serologies 
1/µl, protein 
0.68g/l, normal 
glucose level 
(4.0 mmol/l) 
empirical antibiotic 
tx, dexamethasone 
(stopped after 
infection was ruled 
out). Myoclonic 
jerks and NCSE 
after 3 days. 
Recovery within 14 
days. 
the patient and his family 
decided against re-challenge of 
cetuximab. The patient was 
transferred to the hospice where 
he died 4 weeks later. II 
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* We identified one additional case report with aseptic meningitis (dosage 100mg/m2) from a phase 1 study [8]. With no further details available on this patient we did not 
include it in the table.  
 
† Treatment with cetuximab was continued after the positive re-challenge, but no further adverse events occurred on exposures 3 and following. 
 
‡ Based on the reported number of segmented polymorphonuclear leukocytes (459/µl), that made up 87% of all cells, a total CSF cell count of 528/µl was calculated. 
 
§ Nagovskiy and colleagues stated: „CSF evaluation showed 214 nucleated cells, 15 red blood cells, 81 segmented cells, and seven lymphocytes“ without providing further 
details such as total CSF cell count and whether these numbers were per µl. Contacting the authors for clarification of the CSF cell count in this patient remained unsuccessful. 
 
II The further treatment options were limited due to the failure of carboplatin and paclitaxel as well as preexisting end-stage renal disease and dialysis three times a week. The 
administration of methotrexate has been reported in patients with end stage renal disease but daily dialysis was necessary. In palliative situation and short life expectancy we did 
not consider this an option. Due to difficulties swallowing, the treatment with capecitabine was not possible and continuous infusion of 5-fluorouracil during 5 days could not 
have been administrated because of dialysis.  
 
Abbreviations: CSF=cerebrospinal fluid; CT=computed tomography; HSV=herpes simplex virus; MRI=magnetic resonance imaging; NA=not available; NCSE=non-convulsive 
status epilepticus; NR=not reported; NSCLC=non-small cell lung cancer; PCR=polymerase chain reaction. 
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